Search Results - "Newhall, Kathryn J."

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma by Young, Mary H., Pietz, Greg, Whalen, Elizabeth, Copeland, Wilbert, Thompson, Ethan, Fox, Brian A., Newhall, Kathryn J.

“…This study sought to understand how the programmed death ligand 1 (PD-L1) inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell…”
Get full text

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk by Harrington, Kimberly H, Gudgeon, Chelsea J, Laszlo, George S, Newhall, Kathryn J, Sinclair, Angus M, Frankel, Stanley R, Kischel, Roman, Chen, Guang, Walter, Roland B

“…The CD33/CD3-bispecific T-cell engaging (BiTE) antibody construct, AMG 330, potently lyses CD33+ leukemic cells in vitro. Using specimens from 41 patients with…”
Get full text

Mutations Affecting the SAND Domain of DEAF1 Cause Intellectual Disability with Severe Speech Impairment and Behavioral Problems by Vulto-van Silfhout, Anneke T., Rajamanickam, Shivakumar, Jensik, Philip J., Vergult, Sarah, de Rocker, Nina, Newhall, Kathryn J., Raghavan, Ramya, Reardon, Sara N., Jarrett, Kelsey, McIntyre, Tara, Bulinski, Joseph, Ownby, Stacy L., Huggenvik, Jodi I., McKnight, G. Stanley, Rose, Gregory M., Cai, Xiang, Willaert, Andy, Zweier, Christiane, Endele, Sabine, de Ligt, Joep, van Bon, Bregje W.M., Lugtenberg, Dorien, de Vries, Petra F., Veltman, Joris A., van Bokhoven, Hans, Brunner, Han G., Rauch, Anita, de Brouwer, Arjan P.M., Carvill, Gemma L., Hoischen, Alexander, Mefford, Heather C., Eichler, Evan E., Vissers, Lisenka E.L.M., Menten, Björn, Collard, Michael W., de Vries, Bert B.A.

“…Recently, we identified in two individuals with intellectual disability (ID) different de novo mutations in DEAF1, which encodes a transcription factor with an…”
Get full text

Dynamic Anchoring of PKA Is Essential during Oocyte Maturation by Newhall, Kathryn J., Criniti, Amy R., Cheah, Christine S., Smith, Kimberly C., Kafer, Katherine E., Burkart, Anna D., McKnight, G. Stanley

“…In the final stages of ovarian follicular development, the mouse oocyte remains arrested in the first meiotic prophase, and cAMP-stimulated PKA plays an…”
Get full text

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML by Laszlo, George S., Gudgeon, Chelsea J., Harrington, Kimberly H., Dell'Aringa, Justine, Newhall, Kathryn J., Means, Gary D., Sinclair, Angus M., Kischel, Roman, Frankel, Stanley R., Walter, Roland B.

“…CD33 is a valid target for acute myeloid leukemia (AML) but has proven challenging for antibody-drug conjugates. Herein, we investigated the cellular…”
Get full text

Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel by Olson, N Eric, Ragan, Seamus P, Reiss, David J, Thorpe, Jerill, Kim, Yeonhee, Abramson, Jeremy S, McCoy, Candice, Newhall, Kathryn J, Fox, Brian A

“…In the TRANSCEND NHL 001 study, 53% of patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) achieved…”
Get full text

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients by Frerichs, Kristine A., Verkleij, Christie P. M., Dimopoulos, Meletios A., Marin Soto, Jhon A., Zweegman, Sonja, Young, Mary H., Newhall, Kathryn J., Mutis, Tuna, van de Donk, Niels W. C. J.

“…Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will…”
Get full text

Evidence for Endotoxin Contamination in Plastic Na+-Heparin Blood Collection Tube Lots by NEWHALL, Kathryn J, DIEMER, Geoffrey S, LESHINSKY, Natalia, KERKOF, Keith, CHUTE, Hilary T, RUSSELL, Chris B, REES, William, WELCHER, Andrew A, PATTERSON, Scott D, MEANS, Gary D

“…Biomarker assays are often conducted on whole blood samples in the course of drug development studies. Because bacterial lipopolysaccharide (LPS) (endotoxin)…”
Get full text

Mutations Affecting the SAND Domain of DEAF1 Cause Intellectual Disability with Severe Speech Impairment and Behavioral Problems by Vulto-van Silfhout, Anneke T., Rajamanickam, Shivakumar, Jensik, Philip J., Vergult, Sarah, de Rocker, Nina, Newhall, Kathryn J., Raghavan, Ramya, Reardon, Sara N., Jarrett, Kelsey, McIntyre, Tara, Bulinski, Joseph, Ownby, Stacy L., Huggenvik, Jodi I., McKnight, G. Stanley, Rose, Gregory M., Cai, Xiang, Willaert, Andy, Zweier, Christiane, Endele, Sabine, de Ligt, Joep, van Bon, Bregje W.M., Lugtenberg, Dorien, de Vries, Petra F., Veltman, Joris A., van Bokhoven, Hans, Brunner, Han G., Rauch, Anita, de Brouwer, Arjan P.M., Carvill, Gemma L., Hoischen, Alexander, Mefford, Heather C., Eichler, Evan E., Vissers, Lisenka E.L.M., Menten, Björn, Collard, Michael W., de Vries, Bert B.A.

Get full text

Deletion of the RIIβ-Subunit of Protein Kinase A Decreases Body Weight and Increases Energy Expenditure in the Obese, Leptin-Deficient ob/ob Mouse by Newhall, Kathryn J, Cummings, David E, Nolan, Michael A, McKnight, G. Stanley

“…Disruption of the RIIβ regulatory subunit of protein kinase A (PKA) results in mice with a lean phenotype, nocturnal hyperactivity, and increased resting…”
Get full text

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) by Jain, Nitin, Chevallier, Patrice, Liu, Hongtao, Schiller, Gary J., Méar, Jean-Baptiste, DeAngelo, Daniel J., Curran, Kevin J, Grupp, Stephan, Baruchel, Andre, Balsat, Marie, LaCroce, Alexandra, Roudet, Caroline, Korngold, Ana B., Newhall, Kathryn J., Laille, Eric, Lee, Daniel J., Frattini, Mark G., Larson, Richard A., Boissel, Nicolas

“…Introduction: UCART22 is a genetically modified allogeneic T-cell product manufactured from healthy donor cells. Donor-derived T-cells are transduced using a…”
Get full text

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) by Abramson, Jeremy S., Ramakrishnan, Aravind, Pierola, Ana Alfonso, Braunschweig, Ira, Cartron, Guillaume, Thieblemont, Catherine, Pérez-Simón, Jose A., Barba, Pere, Riedell, Peter A., Solano, Carlos, Gastinne, Thomas, LaCroce, Alexandra, Thomas, Denise, Poirot, Camille, Meadows, Sarah, Newhall, Kathryn J., Lee, Daniel J., Frattini, Mark G., Bachy, Emmanuel

“…Background: UCART20x22 is a dual targeted allogeneic CAR T-cell product candidate generated from healthy donor T-cells. Donor-derived T-cells are transduced…”
Get full text

Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001 by Abramson, Jeremy S., Palomba, Maria Lia, Arnason, Jon E., Lunning, Matthew Alexander, Solomon, Scott R., Farazi, Thalia, Garcia, Jacob, Xie, Benhuai, Newhall, Kathryn J., Dehner, Christine, Siddiqi, Tanya

“…Abstract only 7515 Background: No clinical studies have yet evaluated CAR T cell therapies in pts with R/R B-cell NHL who have secondary CNS lymphoma. We…”
Get full text

Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001 by Wang, Michael, Gordon, Leo I., Palomba, Maria Lia, Abramson, Jeremy S., Andreadis, Charalambos, Ghosh, Nilanjan, Lunning, Matthew Alexander, Maloney, David G., Farazi, Thalia Andrea, Garcia, Jacob, Xie, Benhuai, Newhall, Kathryn J., Dehner, Christine, Siddiqi, Tanya

“…Abstract only 7516 Background: Most pts with MCL relapse after first-line immunochemotherapy, with poor responses to salvage therapy. We report initial…”
Get full text

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk by Harrington, Kimberly H., Gudgeon, Chelsea J., Laszlo, George S., Newhall, Kathryn J., Sinclair, Angus M., Frankel, Stanley R., Kischel, Roman, Chen, Guang, Walter, Roland B.

“…Background: Recent studies have demonstrated that AMG 330, a novel CD33/CD3-directed bispecific T-cell engaging (BiTE¨) antibody, is highly active against…”
Get full text

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells by Krupka, Christina, Brauneck, Franziska, Lichtenegger, Felix S, Kufer, Peter, Kischel, Roman, Zugmaier, Gerhard, Köhnke, Thomas, Altmann, Torben, Schneider, Stephanie, Fiegl, Michael, Spiekermann, Karsten, Sinclair, Angus M, Newhall, Kathryn J, Frankel, Stanley R, Baeuerle, Patrick, Hiddemann, Wolfgang, Riethmüller, Gert, Subklewe, Marion

“…Bispecific T-cell engager (BiTE®) antibodies represent a promising tool for anti-leukemic immunotherapy. The CD19/CD3-bispecific antibody blinatumomab was…”
Get full text

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells by Krupka, Christina, Kufer, Peter, Kischel, Roman, Zugmaier, Gerhard, Köhnke, Thomas, Lichtenegger, Felix S, Schnorfeil, Frauke M, Altmann, Torben, Schneider, Stephanie, Fiegl, Michael, Spiekermann, Karsten, Sinclair, Angus M, Newhall, Kathryn J, Frankel, Stanley R, Baeuerle, Patrick, Hiddemann, Wolfgang, Riethmüller, Gert, Subklewe, Marion

“…Antibody-based immunotherapy represents a promising strategy to target and eliminate chemoresistant leukemic cells in acute myeloid leukemia (AML). In our…”
Get full text

Deletion of the RIIbeta-subunit of protein kinase A decreases body weight and increases energy expenditure in the obese, leptin-deficient ob/ob mouse by Newhall, Kathryn J, Cummings, David E, Nolan, Michael A, McKnight, G Stanley

“…Disruption of the RIIbeta regulatory subunit of protein kinase A (PKA) results in mice with a lean phenotype, nocturnal hyperactivity, and increased resting…”
Get full text